These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 11079615)

  • 1. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
    Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
    Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
    Tünger A; Aydemir S; Uluer S; Cilli F
    Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the MicroScan system and the agar dilution assay for Quinupristin/Dalfopristin susceptibility of Enterococcus faecium.
    Kim YR; Kim SI; Hur JA; Kim YJ; Wie SH; Park YJ; Kang MW
    Ann Clin Lab Sci; 2007; 37(3):260-2. PubMed ID: 17709691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan.
    Lutfor AB; Kikuchi T; Tokue Y; Takahashi H; Shoji S; Fujimura S; Nukiwa T; Watanabe A
    Chemotherapy; 1998; 44(5):318-23. PubMed ID: 9732146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study using standardized methodology for antimicrobial susceptibility of gram-positive cocci isolated from the Puerto Rico Medical Center.
    Rodríguez JL; Vázquez GJ; Bermúdez M; De Orbeta J; García Y; Rivera Y; Robledo IE
    P R Health Sci J; 2002 Dec; 21(4):343-7. PubMed ID: 12572243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activities of quinupristin/dalfopristin in combination with vancomycin and gatifloxacin against Staphylococcus aureus and Enterococcus faecium clinical isolates].
    Gülden E; Ermertcan S
    Mikrobiyol Bul; 2009 Jan; 43(1):53-60. PubMed ID: 19334380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.
    Dowzicky M; Nadler HL; Feger C; Talbot G; Bompart F; Pease M
    Am J Med; 1998 May; 104(5A):34S-42S. PubMed ID: 9684656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China.
    Wang S; Guo Y; Lv J; Qi X; Li D; Chen Z; Zhang X; Wang L; Yu F
    BMC Microbiol; 2016 Oct; 16(1):246. PubMed ID: 27769188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
    Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
    Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.
    Duh RW; Singh KV; Malathum K; Murray BE
    Microb Drug Resist; 2001; 7(1):39-46. PubMed ID: 11310802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci.
    Singh KV; Malathum K; Murray BE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3640-3. PubMed ID: 11709359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.
    Allen GP; Cha R; Rybak MJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2606-12. PubMed ID: 12121940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S; Iwasawa H; Iino S; Shimada J
    Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
    Li JT; Li Y; Wang J;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.